{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T14:14:20Z","timestamp":1724508860192},"reference-count":18,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archives de P\u00e9diatrie"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.arcped.2017.01.018","type":"journal-article","created":{"date-parts":[[2017,2,24]],"date-time":"2017-02-24T22:16:48Z","timestamp":1487974608000},"page":"439-444","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Bilan fran\u00e7ais des effets ind\u00e9sirables du vaccin Pr\u00e9venar 13 \u00ae"],"prefix":"10.1016","volume":"24","author":[{"given":"M.-S.","family":"Agier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Marchand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Paret","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Gautier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.-P.","family":"Jonville-B\u00e9ra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.arcped.2017.01.018_bib0005","first-page":"258","article-title":"Licensure of a 13-valent pneumococcal conjugate vaccine (PCV13) and recommendations for use among children \u2013\u00a0Advisory Committee on Immunization Practices (ACIP)","volume":"59","author":"Centers for Disease Control and Prevention (CDC)","year":"2010","journal-title":"Morb Mortal Wkly Rep"},{"key":"10.1016\/j.arcped.2017.01.018_bib0010","first-page":"109","article-title":"Calendrier vaccinal 2011. Avis du haut conseil de la sant\u00e9 publique","volume":"10","year":"2011","journal-title":"Bull Epidemiol Hebdomadaire"},{"key":"10.1016\/j.arcped.2017.01.018_bib0015","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.arcped.2007.01.018","article-title":"Suivi de pharmacovigilance du vaccin Prevenar\u00ae","volume":"14","author":"Bensouda-Grimaldi","year":"2007","journal-title":"Arch Pediatr"},{"key":"10.1016\/j.arcped.2017.01.018_bib0020","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2165\/00002018-200225020-00003","article-title":"Hypotonic-hyporesponsive episodes following pertussis vaccination","volume":"25","author":"Gold","year":"2002","journal-title":"Drug Saf"},{"key":"10.1016\/j.arcped.2017.01.018_bib0025","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1542\/peds.91.6.1158","article-title":"Severe reactions associated with diphtheria-tetanus-pertussis vaccine: detailed study of children with seizures, hypotonic-hyporesponsive episodes, high fevers, and persistent crying","volume":"91","author":"Blumberg","year":"1993","journal-title":"Pediatrics"},{"key":"10.1016\/j.arcped.2017.01.018_bib0030","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1136\/bmj.316.7135.876","article-title":"Collapse reactions after whole cell pertussis vaccination: pertussis remains a bigger risk than collapse after vaccination","volume":"316","author":"Miller","year":"1998","journal-title":"BMJ"},{"key":"10.1016\/j.arcped.2017.01.018_bib0035","unstructured":"R\u00e9sum\u00e9 des caract\u00e9ristiques du produit Prevenar 13\u00ae. Disponible sur internet\u00a0: URL\u00a0: http:\/\/www.ema.europa.eu\/docs\/fr_FR\/document_library\/EPAR__Product_Information\/human\/001104\/WC500057247.pdf [consult\u00e9 le 20\/11\/2014]."},{"key":"10.1016\/j.arcped.2017.01.018_bib0040","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jpeds.2007.02.013","article-title":"Immunogenicity and safety of a combination diphtheria, tetanus toxoid, acellular pertussis, hepatitis B, and inactivated poliovirus vaccine coadministered with a 7-valent pneumococcal conjugate vaccine and a Haemophilus influenzae type b conjugate vaccine","volume":"151","author":"Pichichero","year":"2007","journal-title":"J Pediatr"},{"key":"10.1016\/j.arcped.2017.01.018_bib0045","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1136\/ebm1049","article-title":"Randomised controlled trial: prophylactic paracetamol at the time of infant vaccination reduces the risk of fever but also reduces antibody response","volume":"15","author":"Homme","year":"2010","journal-title":"Evid Based Med"},{"key":"10.1016\/j.arcped.2017.01.018_bib0050","doi-asserted-by":"crossref","first-page":"5349","DOI":"10.1016\/j.vaccine.2013.09.008","article-title":"Safety and immunogenicity of 13-valent pneumococcal conjugate vaccine in infants: a meta-analysis","volume":"31","author":"Ruiz-Arag\u00f3n","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.arcped.2017.01.018_bib0055","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1016\/j.vaccine.2013.03.040","article-title":"Postlicensure surveillance for pre-specified adverse events following the 13-valent pneumococcal conjugate vaccine in children","volume":"31","author":"Tseng","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.arcped.2017.01.018_bib0060","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1016\/j.vaccine.2015.02.005","article-title":"Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine administered to older infants and children na\u00efve to pneumococcal vaccination","volume":"33","author":"Wysocki","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.arcped.2017.01.018_bib0065","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1046\/j.1365-2125.2001.00341.x","article-title":"Sudden unexpected death in infants under 3\u00a0months of age and vaccination status \u2013\u00a0a case-control study","volume":"51","author":"Jonville-B\u00e9ra","year":"2001","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.arcped.2017.01.018_bib0070","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1097\/00006454-199601000-00010","article-title":"Thrombocytopenic purpura after measles, mumps and rubella vaccination","volume":"15","author":"Jonville-Bera","year":"1996","journal-title":"Pediatr Infec Dis J"},{"key":"10.1016\/j.arcped.2017.01.018_bib0075","series-title":"Impact de la vaccination par le vaccin pneumococcique conjugu\u00e9 sur l\u2019\u00e9pid\u00e9miologie des infections invasives \u00e0 pneumocoques en France 1998\u20132010. Point du 07\/12\/2011","author":"Lepoutre","year":"2011"},{"key":"10.1016\/j.arcped.2017.01.018_bib0080","doi-asserted-by":"crossref","first-page":"6232","DOI":"10.1016\/j.vaccine.2013.10.032","article-title":"Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway","volume":"31","author":"Steens","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.arcped.2017.01.018_bib0085","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S1473-3099(15)70044-7","article-title":"Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4\u00a0years after its introduction: an observational cohort study","volume":"15","author":"Waight","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.arcped.2017.01.018_bib0090","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1183\/13993003.01451-2015","article-title":"Effects of PCV7\u00a0and PCV13\u00a0on invasive pneumococcal disease and carriage in Stockholm, Sweden","volume":"47","author":"Galanis","year":"2016","journal-title":"Eur Respir J"}],"container-title":["Archives de P\u00e9diatrie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929693X17300441?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929693X17300441?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,24]],"date-time":"2022-07-24T19:50:25Z","timestamp":1658692225000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0929693X17300441"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":18,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["S0929693X17300441"],"URL":"https:\/\/doi.org\/10.1016\/j.arcped.2017.01.018","relation":{},"ISSN":["0929-693X"],"issn-type":[{"value":"0929-693X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bilan fran\u00e7ais des effets ind\u00e9sirables du vaccin Pr\u00e9venar 13\u00ae","name":"articletitle","label":"Article Title"},{"value":"Archives de P\u00e9diatrie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arcped.2017.01.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}